Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2 inhibitors: what's the true therapeutic potential?

Blood reviews - 1 Mar 2011

Santos Fabio P S, Verstovsek Srdan

Abstract excerpt

Physicians treating patients with the classic Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs) (polycythemia vera [PV], essential thrombocythemia [ET] and primary myelofibrosis [PMF]) traditionally had few therapeutic drugs available. Spurred by the discovery of activating mu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to JAK2 gene
Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloproliferative Disorders

Source

Open in PubMed Open full text

Identifiers

PMID: 21095048
DOI: 10.1016/j.blre.2010.10.004
PMCID: PMC4406394

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21095048-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2 inhibitors: what's the true therapeutic potential?PMID 21095048Read ↗

JAK2 inhibitors: are they the solution?Semantic proximity Read ↗

New JAK2 inhibitors for myeloproliferative neoplasms.Semantic proximity Read ↗

Therapeutic potential of JAK2 inhibitorsSemantic proximity Read ↗

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?Semantic proximity Read ↗

JAK2 kinase inhibitors and myeloproliferative disordersSemantic proximity Read ↗

Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.Semantic proximity Read ↗

Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome–Negative Myeloproliferative NeoplasmsSemantic proximity Read ↗

Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.Semantic proximity Read ↗

Targeting myeloproliferative neoplasms with JAK inhibitors.Semantic proximity Read ↗

Current treatment concepts of Philadelphia-negative MPN.Semantic proximity Read ↗

The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.Semantic proximity Read ↗

How many JAK inhibitors in myelofibrosis?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.